Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pennsaid · 1 trial · 2 indications
PT will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.
INR will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.
PTT will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.
Platelet Aggregation will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.
| Arm | Type | Description |
|---|---|---|
| Pennsaid, warfarin | OTHER | Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of warfarin for at least 2 months |
| Pennsaid, dabigatran | OTHER | Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of dabigatran for at least 2 months |
| Pennsaid, aspirin and/or clopidogrel | OTHER | Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of aspirin and/or clopidogrel for at least 2 months |
| Name | Type | Description |
|---|---|---|
| Pennsaid | DRUG | Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period. |
Inclusion Criteria: * Male or female adults \> than or equal to 55 * Ambulatory subjects with moderate to severe osteoarthritis (OA) of the knee with symptoms and knee pain for at least 3 months and pain on the majority of days in the last 30 days. * Subjects with bilateral knee OA, the more sympto...
Pennsaid is used for osteoarthritis of the knee. It is a small molecule being developed by Medtronic plc. (MDT) as a topical treatment for knee pain associated with this condition.
Pennsaid targets pain and inflammation in the knee joint through topical application. It is designed to deliver medication directly to the affected area to manage symptoms of osteoarthritis of the knee.
Pennsaid is being developed by Medtronic plc., which trades under the ticker MDT. The company is conducting clinical trials to evaluate the drug for osteoarthritis of the knee.
Pennsaid is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Pennsaid has one completed Phase 3 trial, NCT01511939, which studied the drug's effect on coagulation values in patients with knee osteoarthritis who also take anticoagulants. The trial enrolled 22 participants in the United States.
Pennsaid is the primary name for this drug. No alternative names have been reported in clinical trial records. It is being studied specifically for osteoarthritis of the knee.